NanoVibronix Provides Update on Expanding Access to PainShield

The company is encouraged by proposed legislation backing Medicare reimbursement for non-opioid pain treatments.

Nano v 2 56
NanoVibronix

NanoVibronix, a medical device company using the company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided an update on the efforts to expand access its PainShield product.

“We continue to work closely with The Centers for Medicare & Medicaid Services (CMS) to provide the required documentation for potential reimbursement for PainShield, which we believe will make the device much more readily available for those suffering from chronic pain. We were notified in late September by CMS that PainShield lacked sufficient life expectancy testing and therefore denied reimbursement. We commissioned Carmel Labs in Israel to conduct the testing. This week we received positive interim results with regard to the ongoing lifecycle testing. We plan to submit the results of the test to CMS to backfill our pending application and provide additional evidence as requested," said CEO Brian Murphy.

“Furthermore, we are highly encouraged by the attention the ‘NOPAIN Act’ is garnering from a growing collation of professional and medical organizations and the positive impact the potential passing of the legislation could have on demand for our PainShield,” said Murphy. “The NOPAIN Act is a bipartisan effort to update federal guidelines that would expand access to non-opioid pain management alternatives. Under current law, hospitals receive the same payment from Medicare regardless of whether a physician prescribes an opioid or a non-opioid. If enacted as proposed, the legislation would direct CMS to provide separate Medicare reimbursement for non-opioid treatments used to manage pain, which we believe could provide a seismic increase in demand for products such as our PainShield.”

More in Devices